|
Critical Care Volume 13 Issue 3 |
Viewing options:Associated material:Related literature:- Articles citing this article
- Other articles by authors
- Related articles/pages
Tools: Post to:
|
ResearchTime course of angiopoietin-2 release during experimental human endotoxemia and sepsisPhilipp Kümpers* 1 , Matijs van Meurs* 2,3 , Sascha David1 , Grietje Molema3 , Johan Bijzet3 , Alexander Lukasz1 , Frank Biertz4 , Hermann Haller1 and Jan G Zijlstra2  1Department of Nephrology & Hypertension, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany 2Department of Critical Care, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands 3Department of Pathology and Medical Biology, University Medical Center Groningen, Hanzeplein 19713 GZ Groningen, The Netherlands 4Department of Biometrics, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany author email corresponding author email* Contributed equally
Critical Care 2009,
13:R64doi:10.1186/cc7866 Abstract
Introduction
Endothelial activation leading to vascular barrier breakdown denotes a devastating event in sepsis. Angiopoietin (Ang)-2, a circulating antagonistic ligand of the endothelial specific Tie2 receptor, is rapidly released from Weibel-Palade and has been identified as a non-redundant gatekeeper of endothelial activation. We aimed to study: the time course of Ang-2 release during human experimental endotoxemia; the association of Ang-2 with soluble adhesion molecules and inflammatory cytokines; and the early time course of Ang-2 release during sepsis in critically ill patients.
Methods
In 22 healthy volunteers during a 24-hour period after a single intravenous injection of lipopolysaccharide (LPS; 4 ng/kg) the following measurement were taken by immuno luminometric assay (ILMA), ELISA, and bead-based multiplex technology: circulating Ang-1, Ang-2, soluble Tie2 receptor, the inflammatory molecules TNF-alpha, IL-6, IL-8 and C-reactive protein, and the soluble endothelial adhesion molecules inter-cellular adhesion molecule-1 (ICAM-1), E-selectin, and P-selectin. A single oral dose of placebo or the p38 mitogen activated protein (MAP) kinase inhibitor drug, RWJ-67657, was administered 30 minutes before the endotoxin infusion. In addition, the course of circulating Ang-2 was analyzed in 21 septic patients at intensive care unit (ICU) admission and after 24 and 72 hours, respectively.
Results
During endotoxemia, circulating Ang-2 levels were significantly elevated, reaching peak levels 4.5 hours after LPS infusion. Ang-2 exhibited a kinetic profile similar to early pro-inflammatory cytokines TNF-alpha, IL-6, and IL-8. Ang-2 levels peaked prior to soluble endothelial-specific adhesion molecules. Finally, Ang-2 correlated with TNF-alpha levels (r = 0.61, P = 0.003), soluble E-selectin levels (r = 0.64, P < 0.002), and the heart rate/mean arterial pressure index (r = 0.75, P < 0.0001). In septic patients, Ang-2 increased in non-survivors only, and was significantly higher compared with survivors at baseline, 24 hours, and 72 hours.
Conclusions
LPS is a triggering factor for Ang-2 release in men. Circulating Ang-2 appears in the systemic circulation during experimental human endotoxemia in a distinctive temporal sequence and correlates with TNF-alpha and E-selectin levels. In addition, not only higher baseline Ang-2 concentrations, but also a persistent increase in Ang-2 during the early course identifies septic patients with unfavorable outcome. |